+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 67Years
All Genders
ID06916507

Real-World Study of FoslevodopaFoscarbidopa Effectiveness in Early Advanced Parkinsons Disease in Germany Assessing Motor Symptoms, Quality of Life, and Functioning

Led by AbbVie · Updated on 2026-10-02

125

Participants Needed

19

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Parkinsons disease PD is a neurological disorder that worsens over time with symptoms like tremors, stiffness, and slow movement. This research evaluates how effective foscarbidopafoslevodopa is for German adults in the early stages of advanced PD. Approximately 125 adults prescribed this treatment by their physicians will participate in this observational study. Participants will receive foslevodopafoscarbidopa through subcutaneous infusion as directed by their doctors, following routine clinical practice. The study includes a follow-up period lasting up to 12 months to monitor treatment effects without adding extra burden to participants. During the study, participants will attend regular hospital or clinic visits as part of their usual care. Researchers will measure changes in OFF time hours up to 6 months to assess motor symptom improvements. The study will also look at quality of life and psychosocial functioning while monitoring participants throughout the year-long observation period.

CONDITIONS

Brief Title

Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)

Research Team

M

Medical Information Germany

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here